GAVI names deputy CEO; HIV-positive women respond well to Gardasil;

> The GAVI Alliance has named Anuradha Gupta, formerly the director of India's National Health Mission, as its deputy CEO. Release

> HIV-positive women respond well to Merck's ($MRK) HPV vaccine Gardasil, a study found. More

> Mucosis has entered into a collaboration and licensing agreement with China's Changchun BCHT Biotechnology Co. for its RSV prevention candidate and its Mimopath platform for other disease targets. Release

> A single, inhaled dose of an engineered protein developed by investigators at St. Jude Children's Research Hospital and the University of St. Andrews in the United Kingdom protected mice from a lethal infection with the 2009 H1N1 pandemic virus. Abstract

> NIH is funding an influenza research and surveillance network to improve pandemic preparedness. Release

> FDA scientists have developed an alternative assay that could speed the release of pandemic flu vaccines to the public. More

> Emergent BioSolutions ($EBS) has finished the last licensure-enabling study in a program for its anthrax jab, BioThrax, and submitted the final clinical study report to the Biomedical Advanced Research and Development Authority (BARDA) and the FDA. Release

> DCVax developer Northwest Bio ($NWBO) has secured financing to accelerate the expansion of its European manufacturing. Release

And Finally... Jenny McCarthy made headlines this week, claiming in a piece for the Chicago Sun-Times that she is "not 'anti-vaccine.'" Piece

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.